Wearable Injectors Market is expected to reach US$ 13,880.88 million by 2027

On-Body Segment to Lead Global Wearable Injectors Market During 2020–2027

According to our new research study on “Wearable Injectors Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Application, and End User,” the Wearable Injectors Market is expected to grow from US$ 5,791.23 million in 2019 to US$ 13,880.88 million by 2027; it is estimated to register a CAGR of 11.6% during 2022–2027. The growth of the market is attributed to some key driving factors such as increasing chronic diseases prevalence, technological advancements and design development, and conventional drug delivery system limitations.
 
Based on type, the wearable injectors market is bifurcated on-body injectors and off-body injectors. The on-body segment held the largest share of the market in 2019. However, off-body segment is anticipated to register a CAGR in the market during the forecast period. An on-body injector is a wearable injection device. These devices are becoming popular with cancer patients in the wearable injectors market. Once the device is implemented to the stomach or arm, it slowly delivers the medication over some time. This allows patients to be treated at home without exposure to other infections during treatment. The convenience is making the wearable injectors one of the most in-demand in the forecast period.

Wearable Injectors Market, by Region, 2019 (%)

As the trend of patient care from the clinic to the home continues and a growing number of parenteral biologic products are developed for chronic conditions, there is a greater need for devices that allow patients or non-clinicians to administer injectable medications safely and effectively. In current years, there has been a notable interest in on-body injectors from pharmaceutical companies developing biosimilars. Moreover, many high-volume dosages are being given with the help of body injectors. For instance, Amgen’s Neulasta (peg filgrastim) is delivered as a single 0.6 mL subcutaneous injection one day after a course of chemotherapy to prevent neutropenia and therefore reduce the risk of infection. Amgen’s Onpro on-body injector device is used as a drug delivery device for Neulasta. 

The wearable injectors market, by application, is segment into oncology, diabetes, autoimmune diseases, cardiovascular disease, and other applications. The oncology segment held a larger market share in 2019 and autoimmune disease segment is anticipated to register a higher CAGR during the forecast period. Cancer includes a range of diseases resulting due to the unregulated growth of malignant cells. Cancer is one of the significant health problems with a high mortality rate. Wearable injectors are witnessing a considerable increase in its adoption across the healthcare industry due to its benefits, such as a reduction in disease progression and pain in cancer patients. The on-body injector is placed on the stomach or the back of the arm. It is applied on the last day of the chemotherapy cycle by a healthcare professional. Therefore, the rise in the prevalence of cancer is one of the primary drivers for the growth of the segment.
Going ahead of 1ml formulation, drugs are being developed at volumes that are painful to inject using a conventional auto-injector. That has spurred the growth of wearable injectors that can deliver a higher dose of the drug over a more extended period compared to a daily injection. For instance, Neulasta Onpro is designed to provide Neulasta the next of chemotherapy automatically and saves the trip to the hospital. Most patients can spend the day after intense chemo at home. It is being used by over 600,000 patients and designed to automatically deliver a dose above 45 minutes, about 27 hours after application.

Impact of COVID-19 Pandemic on Wearable Injectors Market

Due to coronavirus spreading, many countries were closing down, causing treatments and doctor’s appointment cancellation. Patients with severe health conditions, such as diabetes, immune diseases, cardiovascular, cancer, vascular needs physical distancing with others; however, delays in such chronic disease treatments is distressing. Hence, for treatment of these diseases the healthcare facilities are preferring wearable injectors to avoid the increase in number of infections. Moreover, in the situation of COVID-19 many companies such as BD, Insulet Corporation, Amgen, and Medtronic are taking the initiative in the treatment of COVID-19. For instance, Medtronic will distribute sensors, infusion sets, and reservoirs, which will be given by Insulin for Life USA to victims on insulin pump therapy, undergoing financial difficulties due to COVID-19.

Amgen, Inc., Medtronic, BD, Insulet Corporation, Gerresheimer AG (Sensile Medical), West Pharmaceutical Services, Inc., Ypsomed AG, Tandem Diabetes Care, Inc., Cequr SA, Debiotech S.A, Elcam Medical, and VALERITAS, INC. are among the leading companies operating in the wearable injectors market. 

Based on type, the wearable injectors market is segmented into on-body injectors and off-body injectors. The on-body injectors segment held the largest share of the market in 2019. However, the off-body injectors segment is estimated to register the highest CAGR in the market during the forecast period. Based on application, the wearable injectors market is segmented into oncology, diabetes, autoimmune diseases, cardiovascular disease, and other applications. The oncology segment held the largest share of the market in 2019. However, the autoimmune disease segment is estimated to register the highest CAGR in the market during the forecast period. Based on end user, the wearable injectors market is segmented into homecare settings, hospital, and clinical and other end users. The homecare setting segment held the largest share of the market in 2019. However, the hospitals and clinics segment is estimated to register the highest CAGR in the market during the forecast period. By geography, the wearable injectors market  is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of APAC), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of MEA), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com